Distinct roles of PARK2, PINK1, and LRRK2 in neuroinflammation: resistance and susceptibility in immune-mediated mouse models
Objective: To investigate the impact of PARK2, PINK1, and LRRK2 deficiency on neuroinflammation in aging, using immune-mediated mouse models. Background: Emerging evidence links mitophagy-related genes, including PARK2 (PARKIN), PINK1, and LRRK2, to immune…Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of Vent-02, a Novel CNS-Penetrant NLRP3 Inhibitor for the Treatment of Parkinson’s Disease
Objective: The objectives of this first-in-human study were to assess the safety, tolerability, pharmacokinetics (PK), food-effect and pharmacodynamics of VENT-02 in healthy volunteers Background: Vent-02…Early Impairment in the Immunomodulatory Function of Mesenchymal Stromal Cells Contributes to Heightened Peripheral and Neuroinflammation in Parkinson’s Disease Insights From In Vivo Chronic PD Rat Model and In Vitro PD iPSC Model
Objective: To assess the timeline dependent changes in endogenous Bone-Marrow-Mesenchymal-Stromal-Cells (BMMSC) in in-vivo chronic PD model and validating these cellular modifications in human iPSC derived…GT-02287 in Parkinson’s Disease: Interim Data from a Phase 1b Study
Objective: To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the brain-penetrant glucocerebrosidase (GCase) modulator GT-02287 in people with Parkinson’s disease with and without a…Modeling Inflammation in GBA-Associated Parkinson’s Disease: Insights into Disease Mechanisms
Objective: This investigation centers on the role of inflammation in GBA-associated Parkinson’s disease (PD), a neurodegenerative disorder characterized by the progressive degeneration of dopaminergic neurons,…A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the NLRP3 Inhibitor Vent-02 in Patients with Mild to Moderate Parkinson’s Disease
Objective: To describe the innovative Phase 2 study design aimed to investigate vent-02 in the treatment of PD. Background: NLRP3 hyperactivation plays a critical role…α-Synuclein Triggers Neuroinflammatory Damage through the suppression of MEF2C
Objective: To explore the effects of microglial myocyte enhancer factor 2C (MEF2C) in neuroinflammation induced by α-synuclein. Background: The abnormal aggregation of α-synuclein (α-syn) is a critical…Peripheral immune profile and neutrophil-to-lymphocyte ratio in Progressive Supranuclear Palsy
Objective: This study aimed to evaluate the peripheral immune profile in patients with Progressive Supranuclear Palsy (PSP) compared with patients with Parkinson’s disease (PD) and…Validating the clinical stage NLRP3 inflammasome inhibitor nibrozetone as a disease-modifying therapeutic for Parkinson’s disease
Objective: We recently confirmed that nibrozetone (RRx-001), a Phase 3 small molecule chemoprotective agent, is a direct NLRP3 inhibitor that is CNS permeable. Nibrozetone displays…Transcriptome analysis of proteasome and inflammation in the substantia nigra of Parkinson’s disease patients: the GEO database.
Objective: In this study, we analyzed transcriptome data regarding protein degradation pathways and inflammation sourced from GEO database. Background: Parkinson's disease (PD) is the second…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 25
- Next Page »